Sugi Predict

Sugi Predict / Compounds / SCHEMBL1650430

SCHEMBL1650430

SCHEMBL1650430

NC(=O)C1=Cc2ccccc2SN1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 3/20 0.33
▸ MAPT P10636 2/20 0.33
▸ HSD17B10 Q99714 2/20 0.33
▸ BCHE P06276 1/20 0.33
▸ ACHE P22303 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ PARP1 P09874 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ RECQL P46063 1/20 0.33
▸ BLM P54132 1/20 0.33
▸ PMP22 Q01453 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ LMNA P02545 1/20 0.31
▸ MAPK1 P28482 1/20 0.31
▸ SCN4A P35499 1/20 0.31
▸ SCN5A Q14524 1/20 0.31
▸ SCN9A Q15858 1/20 0.31
▸ KDM4E B2RXH2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8287 0.84 DAO (0.32) TSHRALDH1A1GPR84
SCHEMBL5836004 0.82 GPR84 (0.30) GPR84
SCHEMBL6542433 0.82 DAO (0.31) TSHRALDH1A1GPR84
SCHEMBL30218272 0.81 GAA (0.35) MAPTTDP1MAPK1KDM4EALDH1A1
SCHEMBL7984058 0.77 TSHR (0.38) TSHRMAPTHSD17B10BCHEPOLB
SCHEMBL7974789 0.74 BCHE (0.39) TSHRHSD17B10BCHECYP2C19TDP1
SCHEMBL7362122 0.74 CA1 (0.42) HSD17B10
SCHEMBL7362125 0.71 PTGS2 (0.44) POLBL3MBTL1LMNAKDM4EHPGD
SCHEMBL3129163 0.71 GPR84 (0.32) GPR84
SCHEMBL4103015 0.71 GPR84 (0.32) GPR84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004019933-A1 METHOD OF PREVENTING OR TREATING ATHEROSCLEROSIS OR RESTENOSIS PHARMACIA & UPJOHN COMPANY (US) 2004-03-11 — — WO claimed
US-6342510-B1 ANTIINFLAMMATORY AGENTS AND ENZYME INHIBITORS G. D. SEARLE & CO. 2002-01-29 — — US claimed
US-4874758-A LIPOXYGENASE INHIBITORS WARNER-LAMBERT COMPANY (US) 1989-10-17 — — US claimed
US-20260121095-A1 Advanced Ion Exchange Membranes And Applications Thereof WILLIAMS RICHARD KENT (US) 2026-04-30 — — US disclosed
US-12350260-B2 Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning UNIVERSITE DE BRETAGNE OCCIDENTALE (FR) 2025-07-08 — — US disclosed
US-20220193048-A1 PROTEASE-ACTIVATED RECEPTOR-2 INHIBITORS FOR THE TREATMENT OF SENSORY NEUROPATHY INDUCED BY A MARINE NEUROTOXIC POISONING UNIVERSITE DE BRETAGNE OCCIDENTALE (FR) 2022-06-23 — — US disclosed
EP-3946332-A1 PROTEASE-ACTIVATED RECEPTOR-2 INHIBITORS FOR THE TREATMENT OF SENSORY NEUROPATHY INDUCED BY A MARINE NEUROTOXIC POISONING Université de Bretagne Occidentale (FR) 2022-02-09 — — EP disclosed
CN-112741817-A Novel effervescent preparation drug delivery system 江苏集萃新型药物制剂技术研究所有限公司 2021-05-04 — — CN disclosed
WO-2020201572-A1 PROTEASE-ACTIVATED RECEPTOR-2 INHIBITORS FOR THE TREATMENT OF SENSORY NEUROPATHY INDUCED BY A MARINE NEUROTOXIC POISONING UNIVERSITÉ DE BRETAGNE OCCIDENTALE (FR) 2020-10-08 — — WO disclosed
CN-108191846-A High-penetration composition and its application 于崇曦 2018-06-22 — — CN disclosed
CN-107320732-A High-penetration composition and its application 于崇曦 2017-11-07 — — CN disclosed
US-4363816-A TREATMENT OF GASTROINTESTINAL DISORDERS BYK GULDEN LOMBERG CHEMISCHE FABRIK GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1982-12-14 — — US disclosed
US-4344929-A Method of delivering drug with aid of effervescent activity generated in environment of use ALZA CORPORATION (US) 1982-08-17 — — US disclosed
US-4317823-A FOR TREATMENT OF GASTROINTESTINAL DISORDERS BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) 1982-03-02 — — US disclosed
EP-0040899-A2 Method of delivering drug with aid of effervescent activity generated in environment of use ALZA CORPORATION (US) 1981-12-02 — — EP disclosed
US-4265874-A Method of delivering drug with aid of effervescent activity generated in environment of use ALZA CORPORATION (US) 1981-05-05 — — US disclosed
US-RE29668-E 4-OXO-1,2-BENZOTHIAZINE-3-CARBOXAMIDE, 1,1-DIOXIDES, ANTIINFLAMMATORY PFIZER INC. (US) 1978-06-13 — — US disclosed
US-RE29669-E CYCLIZATION OF GLYCINEAMIDES PFIZER, INC. (US) 1978-06-13 — — US disclosed
US-3971802-A ANTIINFLAMMATORY PFIZER INC. (US) 1976-07-27 — — US disclosed
US-3954786-A ANTIINFLAMMATORY AGENTS PFIZER INC. (US) 1976-05-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220193048-A1 PROTEASE-ACTIVATED RECEPTOR-2 INHIBITORS FOR THE TREATMENT OF SENSORY NEUROPATHY INDUCED BY A MARINE NEUROTOXIC POISONING PRSS12, TPSB2, F2RL1 TSHR 1546/4885MAPT 2728/4885HSD17B10 2793/4885
US-12350260-B2 Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning PRSS12, TPSB2, F2RL1 TSHR 1546/4885MAPT 2728/4885HSD17B10 2793/4885
US-20260121095-A1 Advanced Ion Exchange Membranes And Applications Thereof MYOC, MB, MYOF TSHR 1922/4885MAPT 3875/4885HSD17B10 4328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.